作者: Kendall H. Lee , Timothy Lukovits , Jonathan A. Friedman
DOI: 10.1385/NCC:4:1:068
关键词:
摘要: The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, efficacy triple-H therapy its precise role in management acute phase SAH remains uncertain. In addition, may carry significant medical morbidity, including pulmonary edema, myocardial ischemia, hyponatremia, renal medullary washout, indwelling catheter-related complications, hemorrhage, edema. This review examines evidence underlying implementation therapy, makes practical recommendations for use patients with SAH.